IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4024
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$165M
Harout Semerjian
GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CBIO GLYCOMIMETICS INC | 36 | 29 | 11 | 63 | - | - | -50.2% | -42.4% | - | - | - | - | 0.0% | 19.0x | $165M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
GLYCOMIMETICS INC (CBIO) receives a "Avoid" rating with a composite score of 35.8/100. It ranks #4024 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CBIO.
View All RatingsROE proxy -50.2% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate GLYCOMIMETICS INC (CBIO) as Avoid with a composite score of 35.8/100 at a current price of $12.65. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
GLYCOMIMETICS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.8/100 places it at rank #4024 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
GLYCOMIMETICS INC represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags GLYCOMIMETICS INC with an Avoid rating, assigning a composite score of 35.8/100 and 1 out of 5 stars. Ranked #4024 of 7,333 stocks, CBIO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CBIO's quality score of 29/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -50.2% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
CBIO registers a value score of just 11/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.04x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
GLYCOMIMETICS INC's investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -42.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CBIO demonstrates moderate momentum with a score of 63/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 24.77 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
GLYCOMIMETICS INC registers a low stability score of 8/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 24.77 and a debt-to-equity ratio of 19.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
GLYCOMIMETICS INC's short interest score of 23/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 24.77), elevated leverage (D/E: 19.00x), micro-cap liquidity risk. At $165M (micro-cap), CBIO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
GLYCOMIMETICS INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4024 of 7,333 overall (45th percentile). Key comparisons include ROE of -50.2% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CBIO currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (8) would have the largest impact on the composite score.
ROE 2543% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 8948% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company anticipates reporting proof-of-concept data in the first quarter of 2027 ASCEND is the first of four clinical trials across the portfolio expected to initiate in 2026 WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ: NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share. BIO-key International, Inc. (NASDAQ: BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023. ReShape Lifesciences Inc. (NASDAQ: RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million public offering. BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares climbed 37.6% to $3.2199 after announcing positive findings from an independent third party audit of the data integrity at TRANQUILITY II Phase 3 trial site. ParaZero Technologies Ltd. (NASDAQ: PRZO) gained 26% to $2.0350. Catalyst Biosciences, Inc. (NASDAQ: CBIO) climbed 18% to $0.5095. Scholar Rock Holding Corporation (NASDAQ: SRRK) gained 16.5% to $8.92. Jefferies upgraded Scholar Rock from Hold to Buy and announced a $20 price target. Stride, Inc. (NYSE: LRN) rose 16.4% to $51.81 after the company reported first-quarter results. OncoCyte Corporation (NASDAQ: OCX) gained 14.4% to $2.86. Urgent.ly Inc. (NASDAQ: ULY) surged 14% to $5.01. GameSquare Holdings, Inc. (NASDAQ: GAME) gained 13.1% to $2.07. Treasure Global Inc. (NASDAQ: TGL) rose 12.8% to $0.4501. PROG Holdings, Inc. (NYSE: PRG) rose 9.3% to $31.14 following upbeat quarterly results. LumiraDx Limited (NASDAQ: LMDX) gained 8.4% to $0.1680 after dipping around 44% on Tuesday. John Bean Technologies Corporation (NYSE: JBT) surged 8.1% to $104.00 after posting strong quarterly earnings. Sonendo, Inc. (NYSE: SONX) shares gained 8% to $0.2483 after falling over 23% on Tuesday. Sonendo recently announced preliminary revenue results for the third quarter. Crown ElectroKinetics Corp. (NASDAQ: CRKN) climbed 8% to $0.2700. Deutsche Bank Aktiengesellschaft (NYSE: DB) rose 6.6% to $10.72 after the company reported a year-over-year increase in third-quarter EPS and sales results. Deutsche Bank Aktiengesellschaft (NYSE: DB) gained 6.6% to $10.72 after the company reported a year-over-year increase in third-quarter EPS and sales results. The Gap, Inc. (NYSE: GPS) climbed 6.2% ...

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. LumiraDx Limited (NASDAQ: LMDX) shares climbed 187.4% to $0.25 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub. Akumin Inc. (NASDAQ: AKU) shares climbed 125% to $0.3279 after the company reached an agreement with Stonepeak to become a private company. Textainer Group Holdings Limited (NYSE: TGH) shares gained 44.5% to $49.33 after the company agreed to be acquired by Stonepeak for $7.4 billion. Twin Ridge Capital Acquisition Corp. (NYSE: TRCA) climbed 17.7% to $8.11. Bright Green Corporation (NASDAQ: BGXX) rose 17.6% to $0.4156. Navios Maritime Holdings Inc. (NYSE: NM) gained 17.2% to $2.21. N Logistics Holdings announced plans to acquire all outstanding shares of common stock of Navios Maritime Holdings not already owned by NLHC for $2.28 per share. Motus GI Holdings, Inc. (NASDAQ: MOTS) gained 16.2% to $0.5576. TeraWulf Inc. (NASDAQ: WULF) rose 16% to $1.2775 FLJ Group Limited (NASDAQ: FLJ) jumped 15.8% to $0.3323. NOVONIX Limited (NASDAQ: NVX) climbed 15.4% to $2.10 The Alkaline Water Company Inc. (NASDAQ: WTER) shares rose 14.6% to $0.2290 after falling 14% on Friday. Nexalin Technology, Inc. (NASDAQ: NXL) surged 13.6% to $0.3580. Farfetch Limited (NYSE: FTCH) rose 13% to $1.7850. EngageSmart, Inc. (NYSE: ESMT) gained 12.1% to $22.65 after the company announced it would be acquired by Vista Equity Partners for $23 per share. Digital Brands Group, Inc. (NASDAQ: DBGI) rose 11.2% to $5.36. Abacus Life, Inc. (NASDAQ: ABL) climbed 8.4% to $6.81. Riot Platforms, Inc. (NASDAQ: RIOT) shares gained ...

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub. Akumin Inc. (NASDAQ: AKU) shares rose 56.6% to $0.2285 in pre-market trading after the company reached an agreement with Stonepeak to become a private company. Next.e.GO N.V. (NASDAQ: EGOX) rose 47.5% to $2.08 in pre-market trading. Next.e.GO Mobile and Athena Consumer Acquisition announced the completion of their previously announced business combination. Textainer Group Holdings Limited (NYSE: TGH) shares gained 42.6% to $48.69 in pre-market trading after the company agreed to be acquired by Stonepeak for $7.4 billion. Harpoon Therapeutics, Inc. (NASDAQ: HARP) shares climbed 37.2% to $9.44 in pre-market trading after the company disclosed Updated interim tolerability and response data from Phase 1/2 clinical trial of T Cell engager HPN328 at ESMO ...

Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday. Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) climbed 58.7% to $2.46. Lipella Pharmaceuticals announced FDA clearance of IND for LP-310 for oral lichen planus. Catalyst Biosciences, Inc. (NASDAQ: CBIO) jumped 44% to $0.5780. MMTec, Inc. (NASDAQ: MTC) gained 37.6% to $2.84 after jumping 51% on Thursday. MMTEC is scheduled to hold its 2023 annual meeting of shareholders on Nov. 10, 2023. Nouveau Monde Graphite Inc. (NYSE: NMG) surged 28% to $2.60 Aravive, Inc. (NASDAQ: ARAV) shares climbed 26.3% to $0.1780 after falling 15% on Thursday. HUB Cyber Security Ltd. (NASDAQ: HUBC) shares jumped 22.7% to $0.6994 after jumping 25% on Thursday. HUB Cyber Security recently reported the strategic appointment of Mr. Noah Hershcoviz as Chief Strategy Officer and a member of the Company’s Board of Directors. Urgent.ly Inc. (NASDAQ: ULY) shares gained 21% to $6.66 after falling around 52% on Thursday. Urgent.ly announced the closing of its acquisition of Otonomo Technologies Ltd. FLJ Group Limited (NASDAQ: FLJ) surged 17.5% to $ 0.2574. Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) gained 17.4% to $0.3199. Versus Systems Inc. (NASDAQ: VS) climbed 16.8% to $0.2150. American Well Corporation (NYSE: AMWL) shares rose 13.9% to $1.0750. American Well and Leidos Holdings have recently won a next-generation contract to provide a hybrid care technology platform designed to power the "Digital First" transformation of the U.S. Military Health System (MHS). Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR) shares climbed 12.1% to $1.11 after falling 12% on Thursday. Knight-Swift Transportation Holdings Inc. (NYSE: KNX) shares gained 11.1% to $50.95 after the company reported better-than-expected third-quarter financial results. Intelligent Living Application Group ...